What is the difference between Cagrilintide and MOTS-c?

Cagrilintide (Cagrilintide (long-acting amylin analog)) is graded A and is Not FDA-approved — combined with semaglutide as CagriSema; Phase 3 in progress. MOTS-c (Mitochondrial-derived peptide MOTS-c) is graded B and is Not FDA-approved — research peptide; multiple early-phase clinical trials. They are commonly compared because they share the categories: metabolic.

Which has stronger clinical evidence — Cagrilintide or MOTS-c?

On our internal evidence scale, Cagrilintide is A and MOTS-c is B. A+ indicates large RCTs plus FDA approval; C indicates primarily preclinical or anecdotal evidence.

What is the typical dose of Cagrilintide vs MOTS-c?

Cagrilintide: Trial range: 0.16–4.5 mg weekly (subcutaneous). MOTS-c: 5–10 mg, 2–3 times weekly (subcutaneous). Always work with a licensed clinician — peptide dosing should be individualized.

Cagrilintide vs MOTS-c

Both Cagrilintide and MOTS-c are used for metabolic. Here's how their evidence, dosing, and regulatory status actually compare.

Cagrilintide

Evidence A

Cagrilintide (long-acting amylin analog)

A once-weekly amylin analog that reduces appetite via the area postrema. Combined with semaglutide ('CagriSema') it has produced ~22% weight loss in trial data.

View full Cagrilintide profile →

MOTS-c

Evidence B

Mitochondrial-derived peptide MOTS-c

A 16-amino-acid mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity in animal models. Among the most promising 'mitokines' for metabolic aging.

View full MOTS-c profile →

Side-by-Side

Attribute	Cagrilintide	MOTS-c
Evidence Grade	A	B
FDA Status	Not FDA-approved — combined with semaglutide as CagriSema; Phase 3 in progress	Not FDA-approved — research peptide; multiple early-phase clinical trials
Typical Dose	Trial range: 0.16–4.5 mg weekly (subcutaneous)	5–10 mg, 2–3 times weekly (subcutaneous)
Clinics Indexed	8	22
Categories	weight-loss, metabolic	metabolic, longevity

Key reported benefits — Cagrilintide

✓Amylin pathway weight loss
✓Synergy with GLP-1
✓Lower-dose tolerability

Key reported benefits — MOTS-c

✓Insulin sensitivity
✓Exercise capacity
✓Metabolic flexibility

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons